Shots:

• The P-III DECLARE-TIMI 58 study involves assessing of Farxiga (dapagliflozin) vs PBO in 17-000 patients with T2D at risk of CV events (MI) across 33 countries in adults
• The P-III DECLARE-TIMI 58 study resulted in reduction of hospitalization for heart failure (hHF) or CV death and 16% reduction in MACE- presented at ACC’s  68th Annual Scientific Session in the US
• Farxiga (dapagliflozin- PO- qd) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to improve glycemic control and is evaluated in P-IIb/III. On February 03-2014 AstraZeneca acquired BMS share of global diabetes alliance including Farxiga

Ref: AstraZeneca | Image: AstraZeneca